Priming of Autoreactive CD8+ T Cells Is Inhibited by Immunogenic Peptides Which Are Competitive for Major Histocompatibility Complex Class I Binding.
- Author:
Sooseong YOU
1
;
Yoon Seok CHOI
;
Seokchan HONG
;
Eui Cheol SHIN
Author Information
- Publication Type:Original Article
- Keywords: Autoimmune disease; Autoreactive CD8+ T cell; Competitive peptide; Major histocompatibility complex class I
- MeSH: Animals; Autoimmune Diseases; Immunization; Major Histocompatibility Complex; Mice; Peptides; T-Lymphocytes; Vitiligo
- From:Immune Network 2013;13(3):86-93
- CountryRepublic of Korea
- Language:English
- Abstract: In the present study, we investigated if priming of autoreactive CD8+ T cells would be inhibited by competitive peptides for major histocompatibility complex (MHC) class I binding. We used a mouse model of vitiligo which is induced by immunization of Kb-binding tyrosinase-related protein 2 (TRP2)-180 peptide. Competitive peptides for Kb binding inhibited IFN-gamma production and proliferation of TRP2-180-specific CD8+ T cells upon ex vivo peptide restimulation, while other MHC class I-binding peptides did not. In mice, the capability of inhibition was influenced by T-cell immunogenicity of the competitive peptides. The competitive peptide with a high T-cell immunogenicity efficiently inhibited priming of TRP2-180-specific CD8+ T cells in vivo, whereas the competitive peptide with a low T-cell immunogenicity did not. Taken together, the inhibition of priming of autoreactive CD8+ T cells depends on not only competition of peptides for MHC class I binding but also competitive peptide-specific CD8+ T cells, suggesting that clonal expansion of autoreactive T cells would be affected by expansion of competitive peptide-specific T cells. This result provides new insights into the development of competitive peptides-based therapy for the treatment of autoimmune diseases.
